Clinical trials: Nocturia
Bladder Function
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep diary and a 3-day bladder diary.
- Trial name
- Nocturia Plt 1 (NCT01029015)
- Testing
- cystometry, polysomnography
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Urinary Bladder Overactive, Overactive Bladder
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for…
- Conditions
- Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
- Trial name
- SYNERGY II (NCT02045862)
- Testing
- Solifenacin succinate, Mirabegron
- Where
- 251 sites in United States, Australia and 30 more
- Volunteers
- 1,829 people
- Sponsor
- Astellas Pharma Europe B.V.
Nocturia, Benign Prostatic Hyperplasia
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied…
- Trial name
- BPH (NCT02106182)
- Testing
- Silodosin, Laboratory tests, 3-days voiding diary
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- JW Pharmaceutical
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Nocturia
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
The purpose of this study is to investigate the potential for co-administration of strong inhibitors or inducers of CYP3A4 to alter the pharmacokinetics of fedovapagon.
- Trial name
- NCT02440841
- Testing
- fedovapagon, Itraconazole, rifampicin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Nocturia
Study of Minirin Melt® in Adult Patients With Nocturia
Observation of safety and efficacy of Minirin Melt® in adult patients with nocturia
- Trial name
- NCT03089073
- Testing
- Desmopressin
- Where
- South Korea
- Volunteers
- 835 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia Due to Nocturnal Polyuria
Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)
To investigate the incidence and risk factors of desmopressin-induced hyponatremia during long-term treatment (1 year [52 weeks]) of MINIRINMELT orally disintegrating (OD) tablets 25μg/50μg (drug) for nocturia caused by nocturnal…
- Trial name
- NOC01 (NCT04329975)
- Testing
- Desmopressin
- Where
- Japan
- Volunteers
- 1,087 people
- Sponsor
- Ferring Pharmaceuticals
Adverse Drug Event
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
A study using medical records to evaluate safety issues for the NOCDURNA drug using national register data from Denmark and Sweden, and a health care register covering parts of Germany.
- Trial name
- NCT04740645
- Testing
- NOCDURNA Cohort, LUTS Cohort
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 1,099,551 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Urge Incontinence
Transcutaneous Tibial Nerve Stimulation: the ZIDA Device Equivalence
Tibial nerve stimulation (TNS) has been shown to be an effective alternative for the management of the overactive bladder (OAB).
- Conditions
- Overactive Bladder, Urge Incontinence, Urinary Incontinence, Urinary Frequency More Than Once at Night
- Trial name
- NCT04470765
- Testing
- Zida
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Exodus Innovations
Urinary Incontinence, Urge Incontinence
UCon Treatment of Overactive Bladder (OAB) in Males
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired…
- Conditions
- Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT05874375
- Testing
- Urge stimulation, Time limited stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Nocturia
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
The purpose of this trial is to demonstrate efficacy of desmopressin ODT against placebo for the treatment of female subjects with nocturia due to nocturnal polyuria, during 12 weeks of treatment.
- Trial name
- NCT02905682
- Testing
- Desmopressin
- Where
- Japan
- Volunteers
- 190 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
VA106483 Dose Response Study in Elderly Males
The main purpose of the study is to evaluate the way VA106483 enters and leaves the blood and tissues over time and how the drug acts on and in the body at various dose levels compared to placebo in the same volunteer.
- Trial name
- NCT00922740
- Testing
- VA106483
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Nocturia
Long Term Safety Assessment of SER120 in Patients With Nocturia
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
- Trial name
- NCT00981682
- Testing
- SER120
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Urinary Incontinence
This Study Will Collect Clinical and Patient Reported Satisfaction Data From Males Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user satisfaction with the PureWick® Male External Catheter in a home setting.
- Trial name
- PUREST-M (NCT06850259)
- Testing
- PureWick® Urine Collection System, UltraFlex™ Self-Adhering Male External Catheter
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- C. R. Bard
Nocturia
Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial
This is a multi-center, double-blind, placebo-controlled study with two weeks of daily oral administration of one of three dose levels of Paxerol or placebo in subjects with nocturia.
- Trial name
- NCT02646826
- Testing
- Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Wellesley Pharmaceuticals, LLC
Nocturia
Efficacy and Safety of VA106483 in Elderly Males
A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and osmolality, circulating coagulation…
- Trial name
- NCT00879138
- Testing
- VA106483, Sugar pill
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Vantia Ltd
Nocturia
A Study of Minirin Melt in Patients With Nocturia
This is a confirmation of safety profile for Minirin Melt in clinical practice.
- Trial name
- NCT01222598
- Where
- 37 sites in Czechia
- Volunteers
- 588 people
- Sponsor
- Ferring Pharmaceuticals
Nocturia
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
- Trial name
- NCT01259128
- Testing
- SER120 Nasal Spray 500 ng/day, SER120 nasal spray 750 ng/day
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia
The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.
- Trial name
- NCT01357356
- Testing
- SER120 (750 ng/day), SER120 (1000 ng/day), SER120 (1500 ng/day)
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Nocturia
Treatment of Patients With Nocturia (Non-PK Study)
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
- Trial name
- NCT00937378
- Testing
- SER120
- Where
- United States
- Volunteers
- 326 people
- Sponsor
- Serenity Pharmaceuticals, Inc.